Rivaroxaban
Rivaroxaban 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Atrial Fibrillation。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
15 项
已进入 III/IV 期
17 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- VA Office of Research and Development
- University of Birmingham
- Odense University Hospital
- Xijing Hospital
- Zunyi Medical College
- Joon Bum Kim
- Population Health Research Institute
- Ottawa Hospital Research Institute
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
英国、丹麦、中国、South Korea、澳大利亚、加拿大、德国、意大利、Russia、Tunisia、美国、Pakistan
正在招募患者的 Rivaroxaban 研究
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
IV 期招募中英国NCT04700826Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
IV 期招募中丹麦NCT06401616Low-dose NOAC Versus GDMT After LAAO
不适用招募中中国NCT05960721Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
IV 期招募中中国NCT06013020Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement
IV 期招募中South KoreaNCT04258488The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial
III 期招募中澳大利亚加拿大德国NCT04284839Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
III 期招募中加拿大NCT05029063START-Register: Survey on Anticoagulated Patients Register
不适用招募中意大利NCT02219984CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention
不适用招募中RussiaNCT07575867Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
IV 期招募中South KoreaNCT06187311Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
不适用招募中TunisiaNCT07869615Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
不适用招募中美国NCT07613840Registry of Patients Prescribed Anticoagulation
不适用招募中美国NCT03504007Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
不适用招募中中国NCT06715007Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™
不适用招募中美国NCT07012291Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease
IV 期招募中中国NCT06978439Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention
IV 期招募中PakistanNCT07243080LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
III 期招募中法国NCT07202897Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation
IV 期招募中PolandNCT06212674Effect of RIVAroxaban in Radial Artery Occlusion Treatment After Cardiac Catheterization
IV 期招募中GreeceNCT06812455inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
IV 期招募中荷兰NCT06581965Anticoagulation in Post MI LV Thrombus Trial in Nepal
IV 期招募中NepalNCT05794399Rivaroxaban in Idiopathic Membranous Nephropathy
IV 期招募中中国NCT07404436Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
不适用招募中PolandNCT07270263
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。